Artificial Organs Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

The global artificial organs market was valued at USD 19.91 Billion in 2025. It is poised to grow at a CAGR of 6.80% during the forecast period of 2026-2035, and reach USD 38.44 Billion by 2035. The market growth is driven by the rising organ failure prevalence, limited donor availability, and advancements in surgical procedures, boosting demand for artificial organs, while supportive regulations and healthcare investments are driving adoption and market growth globally.

Key Market Trends and Insights

• By technology, the mechanical segment accounted for over 66% of revenue in the historical period.
• By fixation, the implantable segment captured more than 73% of the market size in the historical period.
• Based on region, North America held a dominant market share of above 44.32% in the market during the historical period.

Market Size and Forecast

• Market Size (2025): USD 19.91 Billion
• Projected Market Size (2035): USD 38.44 Billion
• CAGR (2026-2035): 6.80%

Artificial Organs Market Overview

The market is expanding due to increasing organ failure and limited donor availability. Rising organ failure and limited donor availability are driving innovation in artificial organs. Advances in medical technology, improved surgical procedures, and growing healthcare investments are enhancing patient care. Increasing awareness of transplant alternatives and supportive regulatory frameworks encourage adoption. Innovations in treatment devices and focus on personalized healthcare are expected to sustain growth and improve clinical outcomes globally during the forecast period. The market reached a value of approximately USD 19.91 Billion in 2025.

Artificial Organs Market Growth Drivers

Government-Funded 3D Bioprinting Initiatives Boost the Market Value

Rising organ failure prevalence and limited donor availability are accelerating the adoption of innovative technologies in regenerative medicine. For instance, in January 2026, the U.S. Advanced Research Projects Agency for Health (ARPA H) awarded grants under its PRINT program to develop universally matched, on demand organs. By leveraging 3D bioprinting organs, this initiative aims to reduce transplant waitlists and reliance on donors. Such investments are expected to accelerate development of artificial organ solutions and expand market opportunities during the forecast period.

Artificial Organs Market Trends

Key trends shaping the market include advanced 3D bioprinting, regenerative medicine, organ-on-chip technology, AI integration, and rising transplant demand.

Growing Innovative Bioprinting Projects Propel Market Expansion

Rising organ failure cases and increasing demand for transplant alternatives are driving innovation in organ engineering. For instance, in January 2026, a USD 25.8 million initiative led by UC San Diego, funded by ARPA H, began developing patient-specific, 3D bioprinted livers. This research offers a scalable organ transplant alternative, reducing dependence on donor organs and lifelong immunosuppression. The project is expected to accelerate the adoption of artificial organ technologies and expand market growth during the forecast period.

Artificial Organs Market Segmentation

Market Breakup by Classification

• Temporary Artificial Organs
• Permanent Artificial Organs

Market Breakup by Type

• Skin or Soft Tissue
• Skin
• Muscles
• Breasts
• Others
• Internal Organs
• Heart
• Kidney
• Pancreas
• Liver
• Blood Vessels
• Others
• Sensory Organs
• Ears
• Eyes

Market Breakup by Technology

• Mechanical
• Electronic

Market Breakup by Fixation

• Implantable
• Externally Worn

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Artificial Organs Market Share

Mechanical Likely to Lead the Market Segment by Technology

The mechanical segment dominated the market by technology, accounting for over 66% of revenue in the historical period. Rising prevalence of organ failure and technological innovation are driving adoption of devices such as ventricular assist devices (VADs) and artificial hearts. Advances in patient care, improved surgical outcomes, and increasing awareness of organ transplant alternatives are expected to support the segment’s continued leadership throughout the forecast period.

Global Artificial Organs Market Analysis by Region

North America held a dominant market share of above 44% in the historical period, supported by advanced healthcare infrastructure and strong investment in medical research. Adoption of innovative solutions like bioartificial kidneys and cochlear implants is rising. Regulatory support, reimbursement policies, and the growing focus on improving patient outcomes are driving market growth in the region, reinforcing North America’s position as a leading hub for artificial organ technologies globally.

Leading Players in the Artificial Organs Market

The key features of the market report comprise strategic initiatives by the leading players. The major companies in the market are as follows:

SynCardia Systems, LLC

Founded in 2001 and headquartered in Tucson, Arizona, SynCardia Systems, LLC is a leading medical device company that pioneers total artificial heart solutions for patients with end-stage heart failure. SynCardia’s flagship product, the Total Artificial Heart, has been commercially approved by regulators including the FDA and Health Canada and is used as a bridge to transplant. Ongoing innovations include fully implantable heart technologies and expanded clinical programs.

Berlin Heart GmbH

Berlin Heart GmbH, headquartered in Berlin, Germany, was established to develop and produce advanced mechanical circulatory support systems, particularly ventricular assist devices that support heart function for patients with severe heart failure. Its products, such as the EXCOR® VAD systems, serve newborns, children, and adults, with global reach and technical support. The company continues R&D investments to enhance device efficiency and patient outcomes.

Carmat SA

Carmat SA is a French biomedical company focused on designing and developing next-generation total artificial heart technologies for patients with advanced biventricular heart failure. The company has expanded the clinical use of its Aeson® artificial heart, with commercial implants performed outside the EU and ongoing research to improve device performance and accessibility. Its innovations aim to offer durable transplant alternatives for patients with limited donor options.

Cochlear Ltd.

Headquartered in Sydney, Australia, and founded in 1981, Cochlear Ltd. is a global leader in implantable hearing solutions. The company designs and manufactures cochlear implant systems and related technologies that restore auditory function for individuals with hearing loss. With a presence in over 180 countries, Cochlear focuses on R&D and strategic acquisitions to advance implant performance and accessibility, supporting improved quality of life for patients worldwide.

Other key players in the market are B. Braun Melsungen AG, and others.

Key Questions Answered in the Artificial Organs Market Report

• What was the artificial organs market value in 2025?
• What is the artificial organs market forecast outlook for 2026-2035?
• What major factors aid the demand for artificial organs market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major artificial organs market trends?
• Which classification is expected to dominate the market segment?
• Which type is expected to dominate the market segment?
• Which technology is projected to lead the market segment?
• Which fixation is likely to lead the market segment?
• Who are the key players in the artificial organs market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?